Alivus Life Sciences Limited has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a total income of ₹6,628.15 million and a net profit of ₹1,600.76 million. These results were approved by the Board of Directors and have undergone a limited review by the statutory auditors.
Alivus Life Sciences Reports Q1 FY27 Financial Results
Alivus Life Sciences Limited has officially released its unaudited financial results for the first quarter of the financial year ending June 30, 2026. The announcement, made on July 30, 2026, details the company’s performance and financial position for the period.
Key Financial Highlights for Q1 FY27
During the quarter, Alivus Life Sciences reported a total income of ₹6,628.15 million. The company’s expenses for the same period amounted to ₹4,505.92 million. This led to a profit before tax of ₹2,122.23 million. After accounting for tax expenses of ₹521.47 million, the net profit attributable to equity holders for the quarter stood at ₹1,600.76 million.
Comparative Performance
The results show a comparative overview against the previous quarter (ended March 31, 2026) and the same quarter in the prior year (ended June 30, 2025). For the quarter ended June 30, 2026, the net profit was ₹1,600.76 million, compared to ₹1,626.61 million in the preceding quarter and ₹1,215.35 million in the corresponding quarter of the previous year.
Other Comprehensive Income
In addition to the net profit, the company also reported other comprehensive income. For the quarter ended June 30, 2026, the total other comprehensive income after tax was ₹3.08 million, leading to a total comprehensive income of ₹1,603.84 million.
Earnings Per Share (EPS)
The basic earnings per share (EPS) for the quarter ended June 30, 2026, were ₹13.04, while the diluted EPS stood at ₹13.01.
Board Approval and Auditor Review
These financial results were approved by the Board of Directors at a meeting held on July 30, 2026. The results have also been subjected to a limited review by the statutory auditors, Walker Chandiok & Co LLP, who have expressed an unmodified review conclusion.
Company Segment
The company operates in a single business segment, identified as Active Pharmaceutical Ingredient (API).
Share Capital Update
As of June 30, 2026, the company’s paid-up equity share capital increased to ₹245.48 million, representing 122,739,448 equity shares of face value ₹2 each, following the allotment of 3,100 equity shares under the Employee Stock Option Scheme, 2021.
Source: BSE
